Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 8626
Technology licensed by a U.S. company to a U.S. company is an Oral Spray, which aims to prevent nausea and vomiting associated with chemotherapy and radiotherapy, as well as postoperative-induced nausea and vomiting. FDA recently agreed to review application for the spray. Note that the lower range of the royalty rate is estimated.
'Licensed Technology' shall mean the Licensor's Patents, the Licensor Know-How and the Drug Master File, collectively, but only with respect to the Exploitation of the Licensed Product.
'Licensed Product(s)' shall mean any dosage of pharmaceutical composition or preparation in finished form labeled and packaged for sale by prescription, overthe-counter or any other method for human application only that contains ondansetron delivered by means of the Licensed Process.
Ondansetron lingual spray , or â€œOLS,â€ our most recently-acquired product candidate,is a novel delivery system that utilizes the vast and highly-absorptive surfaces of the oral cavity (including the area under the tongue) to deliver the drug ondansetron, the most widely used drug to prevent chemotherapy-induced nausea and vomiting , directly into the bloodstream. Administration of ondansetron lingual spray (i.e., spraying on the tongue) will potentially decrease the time necessary to ahcive effective concentrations in the bloodstream, which we believe will more rapidly alleviate nausea and vomiting than conventional oral tablet dosage forms of ondansetron currently available.
IPSCIO Record ID: 328331
In the event that Licensee elects to use the Licensed Trademark in connection with the Exploitation of the Licensed Product in the Territory, then a non-transferable, non-sublicenseable, royalty-bearing, non-exclusive right and license under the Licensed Trademark will be granted for the sole purpose of using the Licensed Trademark to market, distribute and sell the Licensed Product in the Territory, to the full end of the Term for which the Licensed Product is licensed, unless sooner terminated as herein after provided.
Licensed Product shall mean any dosage of pharmaceutical composition or preparation in finished form labeled and packaged for sale by prescription, over-the-counter or any other method only for human application that contains, as the sole active ingredient, the Designated Compound delivered by means of the Licensed Process.
US Patent No. 6,676,931 B2 – Buccal, polar and non-polar spray or capsule
Licensed Trademark shall mean â€œZENSANAâ€ owned by Licensor as evidenced by U.S. Trademark Application Serial No. 78,710,181.
Zensana (ondansetron hydrochloride) is an oral spray 5-HT3 antagonist formulation intended for the prevention of chemotherapy induced nausea and vomiting.
IPSCIO Record ID: 6941
Licensor is the owner of certain technologies, know-how and/or patent rights relating to ondansetron oral spray. Licensee desires to obtain the right and License to use and exploit the above- referenced technologies, know-how and patent rights for the purpose of making and commercializing an ondansetron oral spray product. Licensor is willing to grant Licensee such a License pursuant to the terms and subject to the conditions set forth herein.
Licensed Product means an ondansetron oral spray composition, dosage form, or method of treatment (i) the manufacture, use or sale of which is covered by one or more claims of a Licensor Patent; or (ii) which is made or used, at least in part, utilizing Licensor Know-How.
IPSCIO Record ID: 328330
United States Patent No. 6,676,931 B2 – Buccal, polar and non-polar spray or capsule
Licensed Technology shall mean the Licensor Patents, the Licensor Know-How and the Drug Master File, collectively, but only with respect to the Exploitation of the Licensed Product.
Licensed Product shall mean any dosage of pharmaceutical composition or preparation in finished form labeled and packaged for sale by prescription, over-the-counter or any other method only for human application that contains, as the sole ingredient, the Designated Compound delivered by means of the Licensed Process.
IPSCIO Record ID: 57817
Gastroenteritis, also known as infectious diarrhea, is inflammation of the gastrointestinal tractâ€”the stomach and small intestine.
Gastritis is inflammation of the lining of the stomach.
Gastroenteritis and gastritis – 24 mg strength
Irritable Bowel Syndrome with Diarrhea (IBS-D) – 12 mg strength
Prevention of chemotherapy and radiotherapy induced nausea and vomiting (oncology support) â€“ 24 mg strength
IPSCIO Record ID: 222534
The Licensed Product means any product comprising, incorporating or containing any Compound, or an alternate form of any Compound, including, but not limited to, a pharmaceutically acceptable salt, polymorph, crystal form, prodrug, or solvate of any Compound to the extent such alternate form is claimed in the Licensor Patent Rights.
Rolapitant, a Phase III-ready, oncology supportive-care product candidate, is a potent and selective neurokinin-1 (NK-1) receptor antagonist with an extended plasma half-life that has the potential to improve the management of nausea and vomiting experienced by cancer patients undergoing treatment with emetogenic chemotherapy. Phase II clinical testing of rolapitant for the prevention of nausea and vomiting in cancer patients treated with highly emetogenic chemotherapy demonstrated promising five-day activity following the administration of a single dose.
IPSCIO Record ID: 221
Ondansetron is a serotonin 5-HT3 receptor antagonist used mainly as an antiemetic to treat nausea and vomiting, often following chemotherapy.